In a showdown between 2 antibody drug conjugates, the risk of disease progression or death was lower among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane who received trastuzumab deruxtecan (T-DXd; Enhertu, Daiichi Sankyo/AstraZeneca) than among those who received trastuzumab emtansine (T-DM1; Kadcyla, Genentech). The findings, from interim results of the phase III DESTINY-Breast 03 trial, were published in
The New England Journal of Medicine.
1
